For Geisinger Health Plan members from Pennsylvania traveling to California for substance-use treatment. Geisinger is a vertically-integrated health system — Geisinger Health Plan (insurance) plus 13 hospitals, the Geisinger Medical Group, and the Geisinger Commonwealth School of Medicine — affiliated with Risant Health since 2024. We verify your Geisinger benefits, negotiate out-of-system authorization or single-case agreements when in-system options are clinically inadequate, and handle PA Insurance Department external review.
Sometimes — but Geisinger’s vertically-integrated structure makes out-of-system coverage harder to obtain than at standalone PPO carriers. Geisinger Health Plan is the insurance arm of the broader Geisinger health system based in Danville, PA, with significant footprint across central and northeastern Pennsylvania. The system includes 13 hospitals, the Geisinger Medical Group physician network, and the Geisinger Commonwealth School of Medicine. As a vertically-integrated system, Geisinger strongly prefers care delivered inside its own hospitals and clinical sites — out-of-system coverage typically requires either a single-case agreement (SCA) or a clinical-necessity exception when in-system substance-use treatment options are inadequate. Geisinger joined Risant Health in 2024, a Kaiser-affiliated value-based care system; this affiliation has not yet substantially changed Geisinger’s out-of-state authorization patterns.
If your card lists Geisinger Health Plan, Geisinger Gold Medicare Advantage, Geisinger Marketplace, or Geisinger Health Options, this is the verification path that applies to you.
Inside Geisinger’s network — central and northeastern PA — members access Geisinger’s own substance-use treatment programs through the Geisinger Behavioral Health line, including outpatient counseling, MAT prescribing, IOP at Geisinger sites, and inpatient programs at Geisinger hospitals. The structure is vertically integrated: a Geisinger primary care provider typically refers the member into the SUD treatment line, which stays inside the system.
Outside Geisinger’s network — at Gev’s Recovery in California — coverage is contingent on either an SCA or clinical-necessity exception:
Specific SCA outcomes depend on Geisinger’s UM determination, the strength of the clinical-necessity case for non-Geisinger care, and the member’s existing relationship with Geisinger providers. Our UR team builds the medical-necessity record review by review.
Insurance covers the level of care. The facility decides what the level of care actually delivers. Geisinger members pursuing non-Geisinger treatment have already concluded that in-system options are not the right fit — geographically, clinically, or for family-system reasons. The treatment center receiving them needs to be ready to negotiate with Geisinger, not just bill Geisinger.
Authorization tells you what’s covered; the program decides whether it works.
Geisinger’s vertically-integrated structure makes out-of-system authorization fundamentally different from standalone PPO UM. Every authorization is in effect negotiated against Geisinger’s strong preference for in-system care. Our utilization-review and billing team handles the SCA cycle and the Geisinger-side coordination work.
The decision to escalate is not commercial. It’s clinical. When a client is denied care that’s clinically indicated, we advocate for them — through every step above — to support coverage of the level of care our team believes is medically appropriate.
Geisinger is governed by federal law plus Pennsylvania insurance law.
When we appeal a Geisinger denial, the appeal is built on the clinical documentation, federal MHPAEA, and PA Act 106. All three matter.
Industry standard says 28 days. The clinical literature on substance-use treatment outcomes says something different. The National Institute on Drug Abuse, summarizing decades of research in its Principles of Effective Treatment, states that participation in treatment for less than 90 days is of limited effectiveness for most substance-use disorders, and that better outcomes are associated with longer durations of treatment.
For Geisinger SCA negotiations, this matters specifically. Geisinger’s UM team will sometimes propose 14-to-21-day SCA approvals as a default, with step-down back to Geisinger in-system IOP afterwards. The clinical-necessity case for longer SCA periods leans on the NIDA evidence plus PA Act 106’s strong parity protections.
When concurrent review tries to cut the SCA period short, our UR and medical teams document the clinical reasoning, file additional Geisinger engagement requests, and pursue PA Insurance Department external review when warranted.
Geisinger Health Plan covers a substantial population across central and northeastern Pennsylvania. Some of the populations whose plans we commonly verify:
If your card lists Geisinger Health Plan, Geisinger Gold, Geisinger Marketplace, or Geisinger Health Options, our UR team can identify your specific plan type and walk through the verification with you.
Three steps. No commitment.
Sometimes. Geisinger is vertically integrated and prefers in-system care. Out-of-system coverage at facilities like Gev’s Recovery in California typically requires a Single-Case Agreement (SCA) or clinical-necessity exception. Our team handles the SCA negotiation directly with Geisinger.
An SCA is a one-time contract Geisinger negotiates with an out-of-system provider when in-system options are clinically inadequate. The agreement specifies authorization length, rates, and concurrent-review requirements. SCA approvals can take 24 hours to 2 weeks.
Geisinger joined Risant Health (a Kaiser-affiliated value-based care system) in 2024. The affiliation has not yet substantially changed Geisinger’s authorization patterns or out-of-state coverage rules. Geisinger continues to operate as a distinct vertically-integrated PA system with its own UM framework.
Geisinger covers medical detox at in-system facilities; for out-of-system detox via SCA, authorization windows we typically see are 3 to 14 days when approved.
PA Act 106 (1989) is one of the oldest state-level mental-health and substance-use parity laws in the US. It requires commercial group health plans to cover SUD treatment with parity to medical benefits, predating federal MHPAEA by nearly 20 years. Geisinger members benefit from Act 106’s enforceable coverage rights.
Our medical director conducts a peer-to-peer review with Geisinger’s medical director. If the denial holds, we file Level-1 and Level-2 internal appeals citing PA Act 106 and federal MHPAEA. When internal appeals are exhausted, we file external review with the Pennsylvania Insurance Department. Independent clinical reviewers issue binding decisions.
Geisinger prefers MAT prescribing inside the system. Out-of-system MAT prescription via SCA is uncommon but possible when there’s a clinical reason for non-Geisinger care.
Most Geisinger plans cover treatment of co-occurring psychiatric conditions alongside substance-use treatment when both are clinically indicated, per PA Act 106 and federal MHPAEA. In-system dual-diagnosis programs at Geisinger facilities are well-developed; out-of-system dual-diagnosis via SCA follows the same negotiation process as residential SCA.
Within about 30 minutes you have a written summary of what’s covered, the prior-auth requirements, and any cost-sharing. Verification is free, confidential, and not a commitment to admit.
We are not affiliated with, endorsed by, or sponsored by Geisinger Health Plan, Geisinger Health, Risant Health, the Geisinger Commonwealth School of Medicine, or any related entity; Geisinger trademarks are referenced for informational purposes only. Insurance acceptance is subject to benefit verification. Treatment outcomes vary by individual; statements about the SCA process, peer-to-peer, and appeals process describe Gev’s Recovery’s standard practices and do not guarantee specific coverage decisions by your plan. Gev’s Recovery Center · 19448 Lassen St, Northridge, CA 91324 · CA DHCS license #191288AP.
